TIDMVLG
RNS Number : 3520F
Venture Life Group PLC
16 November 2020
16 November 2020
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Company")
Cardiff University's published in-vitro study reports two
CPC-based mouthwashes completely eradicate SARS-CoV-2 (COVID-19)
within a 30 second exposure
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market, announced on
24 August 2020 its involvement in a UK-led clinical trial, with one
of its key oral care brands containing the powerful Cetylpyridinium
Chloride ("CPC") technology, on those affected with COVID-19. This
independent, multi-centre clinical study, led by Professor David
Thomas at Cardiff University, investigates the possibility that
using over-the-counter mouthwashes containing CPC could help to
reduce the viral load of COVID-19 in the mouth.
Today, the Company provides an update on the recently
published[1] in-vitro results from a separate, independent
laboratory study undertaken at Cardiff University by Dr Richard
Stanton and his colleagues.
In their published in-vitro[2] study, scientists at Cardiff
University concluded that Venture Life's two CPC based mouthwashes
eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log
reduction, equivalent to 99.999%) within a 30 second exposure. The
virus was supplied by Public Health England, unlike other similar
studies reported in the media, which have not used the relevant
COVID-19 virus, but a related strain of it.
Cardiff University went on to state that the 'exact formulation
is also important'. Whilst the CPC technology in Venture Life's
mouthwash proved highly effective in the in-vitro study, they also
tested a third mouthwash, which also contained both CPC and another
ingredient, yet this proved ineffective. Their conclusion was that
active ingredients in mouthwashes were not, on their own, enough to
rely on, but rather it was the construct of the mouthwash
formulations that was the critical determinant of a successful
outcome. The Board considers the composition of Venture Life's
CPC-based mouthwashes to be unique.
The Company looks forward to concluding the human (in-vivo)
clinical study in partnership with Cardiff University and will
update the market with the results in early 2021, once
published.
Professor David Thomas from Cardiff University commented: "At
the start of the study, we were unsure as to which over-the-counter
mouthwashes would be effective against the virus. This in-vitro
study clearly demonstrates that certain CPC mouthwashes inactivate
the SARS-CoV2 (COVID-19) virus following a 30-second exposure in
the lab. With these initially positive results in the laboratory,
our clinical study of CPC-containing mouthwashes continues".
Dr Nick Claydon, Specialist Periodontologist commented: " As a
Dentist, my primary focus is to keep staff and patients safe during
these difficult times. The results of this in-vitro study are very
encouraging and clearly demonstrate the potential for certain
CPC-based mouthwashes to reduce the level of SARS-CoV2 (COVID-19)
in the oral cavity. We certainly hope these positive results will
be reflected in patient studies.
These results indicate the CPC-based mouthwashes used in the
in-vitro study could become an important addition to everyone's
daily routine, together with hand washing, physical distancing and
wearing masks, both now and in the future'.
Jerry Randall, CEO of Venture Life, commented: "Following on
from a very strong H1 2020 performance, where all aspects of the
business out-performed the same period 2019, we view today's
in-vitro results published by Cardiff University as another
positive development for our CPC-based mouthwash range.
The conclusion that our leading CPC-based mouthwash is highly
effective in completely eradicating the actual COVID-19 virus in a
lab setting is important, and we believe should be considered as a
first step in proving the efficacy of CPC-based mouthwashes against
COVID-19 in the oral cavity. We look forward to concluding the
human clinical study in partnership with Cardiff University'.
This announcement contains inside information.
Link to research paper:
https://www.biorxiv.org/content/10.1101/2020.11.13.381079v1
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Joint Broker) 8900
Stephen Keys / Camilla Hume / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
+44 (0) 20 7496
N+1 Singer (Joint Broker) 3000
Shaun Dobson / Carlo Spingardi
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
[1] Published on the biology research platform ( www.biorxiv.org
); has also been submitted to the Journal of Infectious Diseases.
Yet to be peer reviewed
[2] In-vitro - refers to a medical study or experiment, which is
done in the laboratory within the confines of a test tube or
similar
2. Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19):
Emerging and Future Challenges for Dental and Oral Medicine. J Dent
Res 2020; 99:481-7.10.1177/0022034520914246
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESKKPBDDBDBODD
(END) Dow Jones Newswires
November 16, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mag 2023 a Mag 2024